Re: "Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19" by Sengupta et al.

Abstract

Stem Cells and DevelopmentVol. 29, No. 14 Letters To The EditorRe: “Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19” by Sengupta et al.Sai Kiang Lim, Bernd Giebel, Daniel J. Weiss, Kenneth W. Witwer, and Eva RohdeSai Kiang LimInstitute of Molecular and Cellular Biology, Agency for Science, Technology and Research, Singapore, Singapore.#Authors who are members of the International Society for Cell and Gene Therapy (ISCT).Search for more papers by this author, Bernd GiebelInstitute for Transfusion Medicine, University of Duisburg-Essen, University Hospital Essen, Essen, Germany.#Authors who are members of the International Society for Cell and Gene Therapy (ISCT).Search for more papers by this author, Daniel J. WeissDepartment of Medicine, University of Vermont, Burlington, Vermont, USA.#Authors who are members of the International Society for Cell and Gene Therapy (ISCT).Search for more papers by this author, Kenneth W. WitwerDepartment of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.¶Authors who are members of the International Society for Extracellular Vesicles (ISEV).Search for more papers by this author, and Eva RohdeAddress correspondence to: Dr. Eva Rohde, Department of Transfusion Medicine, Salzburger Landeskliniken GesmbH (SALK), Paracelsus Medical University (PMU), University Hospital, Strubergasse 21, Salzburg 5020, Austria E-mail Address: e.rohde@salk.atGMP Unit, Spinal Cord Injury and Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), University Hospital, Salzburg, Austria.Department of Transfusion Medicine, Salzburger Landeskliniken GesmbH (SALK), Paracelsus Medical University (PMU), University Hospital, Salzburg, Austria.Research and Transfer Center for Extracellular Vesicle Theralytic Technologies in Salzburg (EV-TT), Salzburg, Austria.#Authors who are members of the International Society for Cell and Gene Therapy (ISCT).Search for more papers by this authorPublished Online:9 Jul 2020https://doi.org/10.1089/scd.2020.0089AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Re: “Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19” by Sengupta et al.." Stem Cells and Development, 29(14), pp. 877–878FiguresReferencesRelatedDetailsCited byStem cell therapy for COVID-19 pneumonia17 February 2022 | Molecular Biomedicine, Vol. 3, No. 1Meet changes with constancy: Defence, antagonism, recovery, and immunity roles of extracellular vesicles in confronting SARS‐CoV‐230 November 2022 | Journal of Extracellular Vesicles, Vol. 11, No. 12SARS-CoV-2 and extracellular vesicles: An intricate interplay in pathogenesis, diagnosis and treatment31 August 2022 | Frontiers in Nanotechnology, Vol. 4Extracellular vesicles in kidney disease31 May 2022 | Nature Reviews Nephrology, Vol. 18, No. 8Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approachesBMB Reports, Vol. 55, No. 1Mesenchymal Stem Cell-Derived Exosome Therapy of Microbial Diseases: From Bench to Bed3 January 2022 | Frontiers in Microbiology, Vol. 12Made by cells for cells – extracellular vesicles as next-generation mainstream medicines12 January 2022 | Journal of Cell Science, Vol. 135, No. 1Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-1930 June 2021 | npj Regenerative Medicine, Vol. 6, No. 1Mesenchymal stem cell-based therapy and exosomes in COVID-19: current trends and prospects21 August 2021 | Stem Cell Research & Therapy, Vol. 12, No. 1Mesenchymal Stromal Cell Secretome for the Treatment of Immune-Mediated Inflammatory Diseases: Latest Trends in Isolation, Content Optimization and Delivery Avenues27 October 2021 | Pharmaceutics, Vol. 13, No. 11Extracellular Vesicle-Based Therapy for COVID-19: Promises, Challenges and Future Prospects1 October 2021 | Biomedicines, Vol. 9, No. 10The clinical role of host and bacterial-derived extracellular vesicles in pneumoniaAdvanced Drug Delivery Reviews, Vol. 176The Role of Exosomes in the Treatment, Prevention, Diagnosis, and Pathogenesis of COVID-1923 June 2021 | European Journal of Pediatric Surgery, Vol. 395Weiss Response to Sengupta et al. (DOI: 10.1089/scd.2020.0095) Daniel J. Weiss, Sai Kiang Lim, Eva Rohde, Kenneth W. Witwer, and Bernd Giebel9 December 2020 | Stem Cells and Development, Vol. 29, No. 24Functional assays to assess the therapeutic potential of extracellular vesicles29 November 2020 | Journal of Extracellular Vesicles, Vol. 10, No. 1Cell-Free Therapies: Novel Approaches for COVID-1918 September 2020 | Frontiers in Immunology, Vol. 11Response to Lim et al. re: “Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19” Vikram Sengupta, Sascha Sengupta, Angel Lazo, Kevin C. Hicok, and Timothy Moseley9 July 2020 | Stem Cells and Development, Vol. 29, No. 14Extracellular Vesicles as Delivery Vehicles of Specific Cellular Cargo2 July 2020 | Cells, Vol. 9, No. 7 Volume 29Issue 14Jul 2020 InformationCopyright 2020, Mary Ann Liebert, Inc., publishersTo cite this article:Sai Kiang Lim, Bernd Giebel, Daniel J. Weiss, Kenneth W. Witwer, and Eva Rohde.Re: “Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19” by Sengupta et al..Stem Cells and Development.Jul 2020.877-878.http://doi.org/10.1089/scd.2020.0089Published in Volume: 29 Issue 14: July 9, 2020Online Ahead of Print:June 10, 2020PDF download